Boron is a trace mineral.
Used in treating yeast infections, improving athletic performance, or preventing osteoporosis.
Current research suggests that boric acid can modulate intercellular calcium levels—with potential implications for cancer therapy—by:
-Altering calcium channel activity and calcium influx,
-Modifying downstream calcium-dependent signaling, and
-Inducing apoptotic pathways preferentially in cancer cells due to their altered calcium handling dynamics.
Abnormal increases in [Ca²⁺]ᵢ can trigger mitochondrial dysfunction and activate calcium-dependent apoptotic pathways. Boric acid has been observed in some cell culture studies to induce apoptosis in cancer cells.
In normal cells, modest changes in [Ca²⁺]ᵢ induced by boric acid may not reach a threshold that triggers apoptosis or other stress responses. This could lead to a relative sparing of normal cells compared to cancer cells.
Pathways:
1.Calcium Signaling Pathway
In many cases, boron appears to normalize dysregulated calcium levels in cancer cells, often leading to an increase in calcium levels that can trigger calcium-dependent apoptotic pathways.
2.Apoptotic Pathways (Intrinsic and Extrinsic).
Direction of Modulation:
• Boron compounds may enhance the activation of apoptotic cascades.
• Typically, an increase in intracellular calcium (as noted above) can further lead to mitochondrial dysfunction, cytochrome c release, and subsequent caspase activation, thereby promoting apoptosis.
3.PI3K/AKT/mTOR Pathway
• Some studies indicate that boron-containing compounds can inhibit this pathway.
• Inhibition of PI3K/AKT/mTOR signaling reduces survival signals and can decrease cellular proliferation and growth in tumor cell.
4.MAPK/ERK Pathway
Boron may modulate the MAPK/ERK cascade by either dampening overactive mitogenic signals or altering the stress response.
• This modulation can lead to reduced proliferation signals and may promote cell cycle arrest in cancer cells.
5.NF-κB Signaling Pathway
• Some reports indicate that boron compounds can suppress NF-κB activity.
• This suppression might be achieved indirectly through modulation of upstream signals (such as changes in calcium or the cellular redox status) leading to decreased transcription of pro-survival and pro-inflammatory genes.
6.Wnt/β-Catenin Pathway
• Inhibition of Wnt/β-catenin signaling may interfere with proliferation and the maintenance of cancer stem cell populations.
ROS:
-ROS induction may be dose related.
-Some studies report that when boron compounds are combined with other treatments (like chemotherapy or radiotherapy), there is a synergistic increase in ROS generation.
Boron’s effects in a cancer context generally lean toward:
• Normalizing dysregulated calcium signaling to push cells toward apoptotic death
• Inhibiting pro-survival pathways such as PI3K/AKT/mTOR and NF-κB
(1) is essential for the growth and maintenance of bone;
(2) greatly improves wound healing;
(3) beneficially impacts the body's use of estrogen, testosterone, and vitamin D;
(4) boosts magnesium absorption;
(5) reduces levels of inflammatory biomarkers, such as high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor α (TNF-α);
(6) raises levels of antioxidant enzymes, such as superoxide dismutase (SOD), catalase, and glutathione peroxidase;
(7) protects against pesticide-induced oxidative stress and heavy-metal toxicity;
(8) improves the brains electrical activity, cognitive performance, and short-term memory for elders;
(9) influences the formation and activity of key biomolecules, such as S-adenosyl methionine (SAM-e) and nicotinamide adenine dinucleotide (NAD(+));
(10) has demonstrated preventive and therapeutic effects in a number of cancers, such as prostate, cervical, and lung cancers, and multiple and non-Hodgkin's lymphoma; and
(11) may help ameliorate the adverse effects of traditional chemotherapeutic agents.
-Note half-life 21 hrs average
BioAv very high, 85-100%
Pathways:
- induce
ROS productionin cancer cells, while reducing ROS in normal cells.
- ROS↑ related:
MMP↓(ΔΨm),
ER Stress↑,
UPR↑,
GRP78↑,
Ca+2↑,(contrary)
Cyt‑c↑,
Caspases↑,
DNA damage↑,
cl-PARP↑,(contrary)
HSP↓,
- Debateable if Lowers AntiOxidant defense in Cancer Cells:
NRF2↓(most contrary),
SOD↓(some contrary),
GSH↓,
Catalase↓(some contrary),
HO1↓(contrary),
GPx↓(some contrary)
- Raises
AntiOxidant
defense in Normal Cells:
ROS↓,
NRF2↑,
SOD↑,
GSH↑,
Catalase↑,
- lowers
Inflammation :
NF-kB↓,
COX2↓,
Pro-Inflammatory Cytokines :
NLRP3↓,
IL-1β↓,
TNF-α↓,
IL-6↓,
- inhibit Growth/Metastases :
TumMeta↓,
TumCG↓,
EMT↓,
IGF-1↓,
VEGF↓,
RhoA↓,
NF-κB↓,
TGF-β↓,
α-SMA↓,
ERK↓
- reactivate genes thereby inhibiting cancer cell growth :
HDAC↓,
P53↑,
HSP↓,
- some indication of Cell cycle arrest :
TumCCA↑,
cyclin D1↓,
cyclin E↓,
CDK2↓,
CDK4↓,
CDK6↓,
- inhibits Migration/Invasion :
TumCMig↓,
TumCI↓,
TNF-α↓,
ERK↓,
EMT↓,
- small indication of inhibiting
glycolysis
:
HIF-1α↓,
cMyc↓,
GRP78↑,
Glucose↓,
- small indication of inhibiting
angiogenesis↓ :
VEGF↓,
HIF-1α↓,
EGFR↓,
- Others: PI3K↓,
AKT↓,
JAK↓,
STAT↓,
Wnt↓,
β-catenin↓,
AMPK,
ERK↓,
- SREBP (related to cholesterol).
- Synergies:
chemo-sensitization,
chemoProtective,
RadioSensitizer,
RadioProtective,
Others(review target notes),
Neuroprotective,
Cognitive,
Renoprotection,
Hepatoprotective,
CardioProtective,
- Selectivity:
Cancer Cells vs Normal Cells
Boron Pathways for Cancer vs Normal cells
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
Label |
Primary Interpretation |
Notes |
| 1 |
Hormone / growth factor signaling (IGF-1, steroid modulation) |
↓ growth-factor-driven proliferation |
↔ optimized endocrine balance |
Driver |
Systemic growth signal modulation |
Boron influences IGF-1, estrogen, and androgen signaling, indirectly reducing proliferative drive in hormone-responsive tumors |
| 2 |
Inflammatory signaling (NF-κB / cytokines) |
↓ pro-tumor inflammation |
↓ inflammatory tone |
Driver |
Anti-inflammatory environment |
Reduced chronic inflammation limits tumor-promoting microenvironmental signals |
| 3 |
Cell membrane / signal transduction stability |
↓ aberrant signaling responsiveness |
↑ membrane and signaling stability |
Secondary |
Signal fidelity normalization |
Boron supports membrane function and receptor signaling fidelity rather than directly inhibiting kinases |
| 4 |
Mineral metabolism (Ca²⁺, Mg²⁺, vitamin D interaction) |
↔ indirect growth restraint |
↑ mineral homeostasis |
Secondary |
Metabolic support vs dysregulation buffering |
Improved mineral balance supports normal cell resilience and systemic metabolic health |
| 5 |
Reactive oxygen species (ROS) |
↑ ROS (secondary, cancer-biased) |
↔ or ↓ ROS (buffered) |
Secondary |
Metabolic-stress–linked oxidative pressure |
ROS increase reflects impaired redox buffering and metabolic stress rather than direct redox chemistry |
| 6 |
Glutathione (GSH) homeostasis |
↓ GSH availability |
↔ maintained |
Secondary |
Reduced antioxidant capacity |
GSH depletion arises from impaired synthesis and NADPH support in cancer cells |
| 7 |
Apoptosis |
↔ minimal induction |
↔ protected |
Phenotypic |
Non-cytotoxic profile |
Boron does not act as a direct apoptotic trigger |
Distinct from compounds of main Redox Driver
| Compound | ROS ↑ mechanism | Category |
| ------------------- | --------------------------- | ------------------- |
| PEITC | Direct electrophilic stress | Redox driver |
| Selenium (selenite) | Redox cycling | Redox driver |
| Thymoquinone | Quinone cycling | Redox driver |
| **Boron** | Metabolic redox imbalance | **Secondary redox** |
|